A primary peptide of the renin angiotensin system (RAS), Angiotensin (Ang) II, is a 19 vasoconstrictor and promotor of atherosclerosis. To counter this, the RAS also consists of peptides and 20 receptors which increase nitric oxide release from the endothelium and decrease nicotinamide adenine 21 dinucleotide phosphate oxidase-related superoxide production. Two peptides, Ang (1-7) and alamandine 22 are vasodilators, by activating the nitric oxide pathway via different receptors in the endothelium. Thus, 23 herein we focus on the similarities and differences between alamandine and Ang (1-7) and the 24 counterbalancing hypothesis on Ang II during endothelial dysfunction and atherosclerosis. 25 26
Introduction 45
Cardiovascular disease (CVD) accounts for 1 in 3 deaths worldwide [1] with increasing prevalence in the 46 Western world. Despite the therapeutic advances for treating CVD [2] , novel interventions are necessary 47 to further reduce this burden. The renin angiotensin system (RAS) is a hormone system that regulates 48 blood pressure, electrolyte balance and plays a crucial role in atherogenesis and thus CVD. 49 Atherosclerosis is a progressive process of arterial wall thickening and is characterised by the deposition 50 of lipoproteins, cholesterol and white blood cells on the innermost layer of blood vessels [3] . 51
Atherogenesis is complex, however 3 distinct stages have been identified. (1) Endothelial dysfunction, 52 which occurs throughout all stages of atherosclerosis; (2) plaque formation, and, (3) thrombosis [4] [5] [6] . 53
These stages occur at the luminal surface of blood vessels and are time-dependent [7] . Endothelial 54 dysfunction is a pathophysiological shift towards a vasoconstrictive and pro-inflammatory state. This is 55 believed to occur mainly due to a reduction in the bio-availability of nitric oxide, possible due to an 56 altered activity of endothelial nitric oxide synthase (eNOS) [8] or an over-activation of the protein kinase 57 C (PKC) signalling pathway [9] coupled with an overproduction of superoxide [10, 11] . Over-activation 58 of RAS has been linked to endothelial dysfunction and may be involved in altering protein kinases, eNOS 59 activity and superoxide production, ultimately regulating atherogenesis. Thus, drugs regulating RAS are a 60 promising therapeutic modality against CVD. 61
The RAS includes a number of peptides and enzymes, including Ang II, angiotensin converting enzyme 1 62 (ACE1), ACE2, angiotensin A (Ang A, where the A is abbreviated for alanine), angiotensin (1-7) (Ang 63
(1-7)), Mas receptor, Mas-related G coupled protein receptor member D (MrgD) and alamandine [12] [13] [14] . 64
The RAS is present in a number of tissues including, blood vessels, myocardium, kidney and brain [15-65 18] . The pathway begins with angiotensinogen, which is formed in the liver and released into the 66 circulation. It is proteolyzed by renin resulting in a the decapeptide, Ang I. Ang I binds to the endothelial 67 cell layer of blood vessels, and ACE1 cleaves the C-terminal dipeptide (L-histidyl-L-leucine) of Ang I to 68
form Ang II [19] [20] [21] (Figure 1) . 69
Ang II and Ang A have vasoconstrictive properties, which act through the angiotensin II type I receptor 70 (AT1) [14, 22] . AT1 is a 41 kDa transmembrane receptor highly expressed in the cardiovascular system 71 and regulates aldosterone secretion and controls blood pressure [23] . Binding of Ang II to AT1 receptor 72 stimulates an array of pathophysiological actions including, vasoconstriction, which elevates blood 73 pressure, endothelial dysfunction (inhibition of NO production) and increases nicotinamide adenine 74 dinucleotide phosphate (NADPH) oxidase activation for superoxide production; leading to the 75 development of cardiac fibrosis, inflammation associated with atherosclerosis and atherosclerotic plaques 76 [24] [25] [26] [27] [28] . In addition, Ang II may act through the angiotensin II type II receptor (AT2) resulting in 77 vasodilatory effects. AT2 is highly expressed in the developing fetus, however, its expression is low in the 78 cardiovascular system but is increased in inflammation, hypertension and atherosclerosis and is 79 vasoactive in human radial arteries [29] . Likewise, alamandine, is hydrolyzed by ACE2 from Ang A or 80 decarboxylated from Ang (1-7), also exerts vasodilatory and anti-hypertensive actions, through the MrgD 81 receptor [12, 30] . Ang (1-7) is also a vasodilator which acts via the Mas receptor, which is related to the 82 MrgD receptor. Therefore, the localization of both the MrgD and the Mas receptor on endothelial cells 83 suggests that both alamandine and Ang (1-7) may play important roles in blood vessel physiology [22, 84 31 ]. In addition, Ang (1-7) exerts an anti-angiogenic role by decreasing proangiogenic hormones such as 85 vascular endothelial growth factor-A [12, 32] . However, there are no reports to demonstrate the effect of 86 alamandine on angiogenesis. Furthermore, ingestion of alamandine/cyclodextrin decreases the 87 accumulation of collagen I, III, and fibronectin in isoproterenol-treated rats, contributing to a decrease in 88 cardiac fibrosis [12] . Interestingly, research performed in our laboratory showed a marked reduction in 89 rat aortic wall elastic fibers after an atherogenic diet for 15 weeks [33] , and thus it would be interesting to 90 determine if alamandine can reduce this pathological effect. Therefore, Ang (1-7) and potentially 91 alamandine acting via their specific receptors, may be able to decrease endothelial cell proliferation and 92 migration, resulting in a decrease in endothelial cell permeability, and thus an attenuation of 93
atherogenesis. 94
Both the Mas and the MrgD receptors are proto-oncogenes. The Mas proto-oncogene was first identified 95 in 1986 where it was noted to facilitate tumorigenesis, and similarly for the overexpression of the MrgD 96 receptor in murine fibroblast cell lines [34, 35] . Thus, if alamandine and Ang (1-7) are to be used as a 97 treatment for CVD, these peptides could affect oncogenesis. Thus, it is important to determine a possible 98 carcinogenic/oncogenic effect in animal models using alamandine and Ang (1-7) in a combined 99 CVD/cancer model. 100
Ang (1-7) counterbalances the effects of Ang II exerted on human cerebral smooth muscle cells [25] . 101
These effects reduce Ang II-induced apoptosis and proliferation [25] . Indeed, in vitro studies show that 102 administration of Ang (1-7) to rat aorta prevents Ang II-stimulated reactive oxygen species (ROS) 103 production [24] and increases NO release resulting in increased vasodilation [36] , and reduces endothelial 104 oxidative stress. We are unaware of studies that demonstrate alamandine counterbalancing Ang II effects 105 on vascular smooth muscle cells and on endothelial cells. It is possible that alamandine may mimic the 106 effects of Ang (1-7), due to the close homology of their amino-acid sequence (Figure 1 and 2). Indeed, 107 alamandine stimulates NO release potentially by eNOS in endothelial cells to induce vasodilation through 108 the MrgD receptor [12] . Thus, combined Ang (1-7)/alamandine would be viable pathways to reduce Ang 109 II-associated endothelial dysfunction (i.e. low NO release from endothelium), Ang II-associated vascular 110 proliferation, and Ang II-associated inflammation during atherosclerosis. 111
Biosynthetic pathway for of Ang (1-7) and Alamandine 112
The RAS exists in the circulatory and tissue system and circulatory-Ang II is synthesized when ACE 113 cleaves the C terminal dipeptide of the renin-catalyzed-angiotensin I [37] . An intracellular form of renin, 114 as well as angiotensin I and both forms of ACE expressed in tissues have been associated with increased 115
intracellular Ang II production [38] . Therefore, the formation Ang (1-7) and alamandine, can also be 116 biosynthesized at a circulatory and tissue level. As revised by Zhang et al (2015) , ACE2 catalyzes 117 angiotensin (1-9) from angiotensin I, so that angiotensin (1-9) can be cleaved by ACE into Ang (1-7). 118
Moreover, Ang II can be directly converted into Ang (1-7) via ACE2 [39] . Also, carboxylase can convert 119
Ang (1-7) to alamandine. Similarly to Ang (1-7), alamandine can be synthesized at the circulatory and 
Factors involved in vascular dysfunction, leading to atherosclerosis 128
The widely studied vasodilator produced by the endothelial layer of blood vessels is the free radical gas, 129
NO [43] . NO contributes to normal vascular homeostasis and reduced NO bioavailability results in 130 endothelial dysfunction [44, 45] . CVD risk factors, such as type 2 diabetes, hypertension, and 131 hypercholesteremia exacerbate the reduction of NO bioavailability thus promoting atherosclerosis. Since 132 atherosclerosis is the primary cause of CVD, the pharmacological drive to reverse endothelial 133 dysfunction, by improving NO release, should improve vascular health and reduce the burden of CVD. In 134 addition, ROS released by cells, including endothelial cells, is a byproduct of oxygen in normal 135 homeostasis. During stress however, ROS is produced in excessive levels leading to cell damage (cellular 136 oxidative stress). In fact, overproduction of Ang II leads to dramatic increase in ROS production by 137 endothelial cells, through the NADPH oxidase enzyme inducing cellular oxidative stress, leading to 138 endothelial dysfunction, endothelial apoptosis and promotion of thrombosis formation [46] [47] [48] . Hence, 139 cellular oxidative stress and reduction in NO, contribute to endothelial dysfunction [49] [50] [51] phospholipase A2 phosphorylation leading to increased production of eNOS-induced NO and cyclic 160 AMP production [36, 62] . Ang (1-7) has also been shown to cause a reduction of mitogen-activated 161 protein kinase (MAPK) phosphorylation concomitant with a reduction of extracellular-signal-regulated 162 kinase (ERK1/2) phosphorylation within endothelial cells [62, 63] , which is likely to be a major anti-163 proliferation pathway induced by Ang (1-7) . 164
A critical role for Ang (1-7)/Ang II has been established in endothelial dysfunction and cellular 165 proliferation. Considering research from this laboratory is clearly providing a vasoactive role for both 166 alamandine and Ang A [22], a trophic or anti-trophic effect on endothelial cells has not as yet been 167 demonstrated. Therefore, future experiments similar to studies conducted for Ang (1-7) will provide the 168 essential information necessary to compare these two heptapeptides. 169 170 (1-7) and Mas receptor counterbalance the effects of Ang II and AT1 receptor 171
Ang
The Mas receptor is a G-coupled protein receptor which is expressed in brain, kidneys, testes, heart and 172 blood vessels of both humans and mice [36, [64] [65] [66] [67] . It is conceivable that Ang (1-7) mediated through the 173
Mas receptor [68], may have beneficial effects in the treatment for CVD. Indeed, Ang (1-7) at 80nM has 174 been shown to protect against hypoxia and cardiomyocyte apoptosis by preventing ROS-induced 175 mitochondrial dysfunction in rat cell lines [69] . This suggests that Ang (1-7) may be protective in specific 176 tissues and that it may act on mitochondria. Furthermore, a number of RAS blockers have been developed 177 in order to reduce the effects of Ang II; such blockers (renin inhibitors, ACE inhibitors and Ang II 178 receptor blockers) all have anti-hypertensive effects [15] . Interestingly, inhibition of Ang II via ACE1 179 blockers increases Ang (1-7) by 5-25-fold in blood [70] and Ang (1-7) may also be involved in the anti-180 depressant effect of ACE1 treatment in hypertensive rats [71] . This suggests that Ang (1-7) alone has an 181 important role in blood pressure regulation via inducing vasodilation protecting endothelial function and 182 hence, cardiovascular related diseases. Since Ang (1-7) is formed by ACE1, increasing its levels could be 183 a viable alternative to inhibition of ACE1 in order to achieve desired plasma Ang (1-7) concentration. 184
Likewise, alamandine has anti-hypertensive properties, enhances vasodilation and reverses endothelial 185 dysfunction in spontaneous hypertensive rats and homocysteine-induced endothelial dysfunction rabbits 186 [12, 72] . Hence, as Ang (1-7) can reverse the negative effects of Ang II on endothelial dysfunction, 187 superoxide production, as well as lowering Ang II-induced atherosclerotic lesions and plaque formation, 188 further studies with alamandine could show similar findings, and together these heptapeptides could 189 reduce the progression of CVD. suggesting that Ang (1-7) may not be a beneficial treatment at severe stages of disease, and that it may 199 potentially exacerbate the development of disease instead. However, more studies report that chronic 200 treatment of Ang (1-7) is able to reduce fat accumulation and inflammation in animal models of liver 201 disease, suggesting Ang (1-7) as a strong anti-inflammatory agent [75] . Thus the model chosen plays a 202 role in the controversial reports of any experiments related to Ang (1-7) as a treatment. 203
Of interest, Ang (1-7) and Ang II both stimulated ERK1/2 phosphorylation and enhanced mesangial cell 204 proliferation [76], further conflicting most reports that demonstrate the opposing effects of Ang (1-7) 205 compared to Ang II [77, 78] . However, when co-administered to rat renal mesangial cells, Ang (1-7) 206 inhibited the stimulatory effects induced by Ang II, which could be blocked by a Mas receptor blocker, 207
A779, yet anti-AT 1 or anti-AT2 receptor blockers had no effect [76] . Hence, although interacting with 208 each other [79], Ang (1-7) specifically acts on the Mas receptor and Ang II specifically acts on the AT1 209 receptor. In human umbilical vein endothelial cells (HUVEC), Ang (1-7) at 1µM had no effect on 210 endothelial cell apoptosis, however when HUVEC are treated with Ang II, Ang (1-7) suppresses 211 apoptosis [80]. This indicates not only the crucial role on endothelial cell survival [62] , but also that Ang 212
(1-7) either interacts with the AT1 receptor by dislodging Ang II binding or interacts with the Mas 213 receptor. Similar findings were observed in aortic vascular cells of ACE2-knockout mice [81] . 214 Furthermore, in Ang II induced endothelial dysfunction, blocking of the AT1 receptor augments the 215 production of NO and improves vasodilation, which are crucial factors in the prevention of hypertension 216 and atherosclerosis [82, 83] . Since, blocking of the AT1 receptor is associated with an increase of Ang (1-217 7), the addition of Ang (1-7) may counterbalance the effects of Ang II induced endothelial dysfunction 218 and may aid in the prevention of atherosclerosis. To this effect, ex vivo treatment of murine aortae with 219
Ang II impairs vasodilation which is reversed by Ang (1-7) [31]; these effects are diminished following 220 treatment with the Mas receptor antagonist, A779. These findings, suggest that endothelial dysfunction 221 induced by Ang II (reduced NO and vasodilation), could be counterbalanced by Ang (1-7) acting through 222 the Mas receptor. Moreover, the studies suggest that the counterbalancing effects caused by Ang (1-7) 223 through the Mas receptor are a compensatory system that is important to balance the over-activity of Ang 224 II through the AT1 receptor. However, the cellular mechanism underlying this theory is not yet clear, 225
although some studies suggest a specific non-competitive inhibition of Ang (1-7) on the AT1 receptor [84, 226 85] . Others suggest that the AT1 receptor and Mas receptor form a hetero-oligomer in order for their 227 effects to be counterbalanced [76, 86] . Further research to establish these initial results are necessary. Alamandine, a heptapeptide, is closely related to the vasodilator Ang (1-7), with only one amino acid 239 difference, whereby the first amino acid of Ang (1-7) is aspartate, and alanine is for alamandine. 240
Therefore, alamandine can be synthesized from Ang (1-7) by decarboxylation of aspartate into alanine. 241
As these peptides have similar amino acid sequence and structure (Figure 1 and 2) , their effects are highly 242 likely to be similar. Through chromatographic approach, it was demonstrated that a peptidase exists in the 243 medulla of sheep brain which converts Ang (1-7) into Ang (1-4) [87] . Although the peptidase was not 244 identified, it was suggested that metalloendopeptidase may have been responsible. More recently, it was 245 noted that the hydrolysis of alamandine may also occur via metalloendopeptidase for Ang (1-7) in kidney 246 tissue [88] . 247
Interestingly, Chinese Hamster Ovary (CHO) cells transfected with Mas receptor and incubated with Ang 248
(1-7) resulted in elevated NO levels and eNOS activity, which was inhibited by the Mas receptor blocker , 249
A779. In addition, wortmannin, a specific phosphatidylinositol 3 (PI3) kinase inhibitor reduced NO levels 250 and eNOS activity in the absence of A779 [36] . Similar effects were also noted in human aortic 251 endothelial cells (HAEC), which constitutively express the Mas receptor [36] , as well as in rat hearts [89] . 252
In addition, Ang (1-7) through the Mas receptor activates the protein kinase B pathway (PKB) in 253 pancreatic islet endothelial cells [62] , increasing eNOS activity and NO production. However, in 254 mesangial cells Ang (1-7) activates Mas receptor via a different protein kinase pathway, PKA, and 255 correlates with increased cyclic AMP [90] . 256
To further understand the similar roles amongst Ang (1-7) and alamandine, we recently demonstrated that 257 ex vivo treatment of alamandine to isolated rabbit aortas reversed homocysteine-induced endothelial 258 dysfunction by activating the PKA pathway for vasorelaxation [72] . Although we demonstrated the 259 presence of MrgD receptor using immunohistochemistry in another study [22] , others have shown that 260 CHO cells transfected with MrgD receptor and cultured with alamandine, high levels of NO is produced 261 but not in normal CHO cells, suggesting that alamandine binds to MrgD receptor to induce NO 262 production via increasing eNOS activity [12] . This specific finding establishes that alamandine binds to 263
MrgD receptor and that the outcome is enhanced NO production through eNOS, the enzyme that produces 264 NO within endothelial cells. Whilst these studies were conducted in non-diseased cells [12] , we 265 previously demonstrated that alamandine was not able to prevent endothelial dysfunction in atherogenic-266 diet fed rabbits, however alamandine is likely to exert more acetylcholine-mediated vasodilation in 267 thoracic and carotid artery compared to acetylcholine-exerted vasodilation alone in these atherogenic 268 vessels [22] . These studies clearly suggest that the role of alamandine may exert beneficial vasodilatory 269 effects on the initial steps of atherosclerosis and may not play a role in advanced stages of atherosclerosis. 270
Possibly, the function and expressions of MrgD receptor on the endothelial cell layer may not be 271 sufficient or efficient when the vessel is completely dysfunctional and, therefore, alamandine has no 272 beneficial effects in such conditions. Hence, early intervention needs to be considered when treating 273 atherosclerosis with alamandine. 274
Moreover, in organ bath experiments, individual incubations of alamandine and Ang (1-7) were not able 275 to reduce Ang II mediated vasoconstriction [22] . Conversely, Ang (1-7) has been shown to reverse Ang 276 II-mediated endothelial dysfunction in mouse aorta [31] . Although the results are conflicting, differing 277 experimental conditions exist. In our study [22] , the vessels were incubated with the RAS peptides and 278 then a dose-response curve to Ang II was constructed, whereas in [31], the vessels were initially 279 incubated with Ang II in organ cultures for 24 hours and then Ang (1-7) was incubated, where 30 minutes 280 after this point a dose-response curve to acetylcholine was constructed [31]. These differences suggest 281 that further studies are required to elucidate the roles of alamandine and Ang (1-7) during diseased states 282 such as atherosclerosis. 283 284
Conclusion 285
Studies from our and other laboratories show that Ang (1-7) and alamandine are able to promote 286 beneficial effects on the cardiovascular system, such as, counterbalancing Ang II-associated endothelial 287 dysfunction and therefore, may reduce the development of Ang II associated atherosclerosis. 288 289 
